注射用阿克拉霉素A固体脂质纳米粒小鼠体内抗肝癌活性及急性毒性研究  

Study on the Antihepatocarcinoma Activity and the Acute Toxicity of Aclacimomycin-A Solid Lipids Nanoparticle for Injection in Mice in Vivo

作　　者：孙世明[1] 何林[1] 吴正中[1] 荣祖元[2] 朱洁[2] 

机构地区：[1]四川省人民医院药剂科,成都市610072 [2]四川省抗菌素工业研究所,成都市610051

出　　处：《中国药房》2005年第18期1372-1374,共3页China Pharmacy

基　　金：四川省科技厅重点科技项目(01SY051-41)

摘　　要：目的:以注射用阿克拉霉素A(ACM)为参比制剂,研究注射用阿克拉霉素A固体脂质纳米粒(ACM-SLN)在裸小鼠体内的抗肝癌活性及急性毒性。方法:将移植肿瘤后的裸小鼠分为对照组、ACM组、ACM-SLN组,各组分别注射相应药物后计算抑瘤率,再取小鼠分别注射ACM和ACM-SLN后计算LD50值。结果:与对照组比较,ACM-SLN组和ACM组抑瘤率分别为78.4%和38.8%,LD50值分别为16.3、18.0mg/kg。结论:ACM-SLN对裸小鼠抗肿瘤作用优于ACM,且毒性未见增加。OBJECTIVE： To study the antihepatocarcinoma activity and toxicity of Aclacimomycin - A solid lipids nanoparticle for injection（ACM-SLN） in nude mice in vivo with ACM for injection as the reference preparation. METHODS： The nude mice were divided into control group, ACM group and ACM-SLN group after tumor transplantation, which were injected with the corresponding medicine before the tumor - inhibition rates of which were calculated, which were then injected with ACM and ACM - SLN, respectively before the LD50 of mice were calculated. RESULTS： Compared with the control group, the tumor inhibition rates of ACM-SLN group and ACM group were 78.4% and 38.8%, respectively, the LD50 of which were 16.3 mg/kg and 18.0mg/kg, respectively. CONCLUSION： The ACM-SLN is superior to ACM in terms of the anti - tumor effect while without the increase of toxicity.

关 键 词：注射用阿克拉霉素A固体脂质纳米粒 注射用阿克拉霉素A 抑瘤率 半数致死量 急性毒性 

分 类 号：R965[医药卫生—药理学] R979.14[医药卫生—药学]